MXN

MXN

moxifloxacin

Manufacturer:

Dexa Medica
Concise Prescribing Info
Contents
Moxifloxacin
Indications/Uses
Susceptible infections in adult patients unable to take oral therapy or who are intolerant to alternative agents, who present w/ acute exacerbations of chronic bronchitis; community-acquired pneumonia; acute bacterial sinusitis; complicated skin & skin structure infections which require initial parenteral therapy followed by oral therapy; complicated intra-abdominal infections due to polymicrobial infections.
Dosage/Direction for Use
IV infusion 400 mg once daily over 1 hr. Recommended treatment duration: Acute exacerbation of chronic bronchitis 5-10 days. Community acquired pneumonia 10 days. Acute sinusitis 7 days. Complicated skin & skin structure infection 7-21 days (sequential IV/oral therapy). Complicated intra-abdominal infection 5-14 days (sequential IV/oral therapy).
Contraindications
Hypersensitivity. History of tendon disease/disorder related to quinolone treatment; symptomatic arrhythmias. Congenital or documented acquired QT prolongation. Electrolyte disturbances, particularly in hypokalemia. Clinically relevant bradycardia. Clinically relevant heart failure w/ reduced left ventricular ejection fraction. Pregnancy & lactation. Childn <18 yr.
Special Precautions
Increased risk of tendinitis & tendon rupture in all ages. Risk is further increased in older patients (>60 yr), patients taking corticosteroids & patients w/ renal, heart or lung transplants. Discontinue treatment at the 1st sign of pain or inflammation; if signs of cardiac arrhythmia occur. Concomitant use of medications that reduce K & Mg level. Patients w/ CNS disorders which may predispose to seizures or lower the seizure threshold; myasthenia gravis; family history of or actual defects in G6PD; for whom Na intake is of medical concern. QT prolongation may lead to an increased risk for ventricular arrhythmias including Torsades de pointes. Anaphylactic reactions can progress to life-threatening shock. Bullous skin reactions eg, Stevens-Johnson syndrome or toxic epidermal necrolysis; fulminant hepatitis leading to liver failure; pseudomembranous colitis. Liver function tests should be performed in cases of liver dysfunction. Avoid exposure to UV irradiation or extensive sunlight during treatment. Consult specialist if vision becomes impaired or or any effects on the eyes are experienced. Not recommended in patients w/ complicated pelvic inflammatory disease for whom an IV treatment is necessary. Not recommended in patients w/ severe hepatic impairment. Elderly.
Adverse Reactions
Inj & infusion site reactions; mycotic superinfections; QT prolongation in patients w/ hypokalemia; nausea, vomiting, GI & abdominal pain, diarrhea; transient increase in transaminase; headache, dizziness; increased gamma-glutamyl-transferase.
Drug Interactions
Administer at least 4 hr before or 8 hr after Al- or Mg-containing antacids, didanosine tab, sucralfate or Fe- or Zn-containing agents. Concomitant use w/ drugs that induce bradycardia or hypokalemia or drugs which induce QT prolongation (neuroleptics, certain anti-infective agents, certain antihistamines). Increased activity of anticoagulants.
MIMS Class
Quinolones
ATC Classification
J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Presentation/Packing
Form
MXN soln for infusion 400 mg/250 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in